Jarno E J Wolters1,2,3, Ralph J S van Mechelen1,2,3, Rana Al Majidi1,2,3, Leonard Pinchuk4,5, Carroll A B Webers1,2, Henny J M Beckers1,2, Theo G M F Gorgels1,2. 1. University Eye Clinic Maastricht, Maastricht University Medical Centre + (MUMC+), Maastricht. 2. Chemelot Institute for Science and Technology (InSciTe), Geleen. 3. School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands. 4. InnFocus, Inc., a Santen Company. 5. Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: Mitomycin C (MMC) is an alkylating agent with extraordinary ability to crosslink DNA, preventing DNA synthesis. By this virtue, MMC is an important antitumor drug. In addition, MMC has become the gold standard medication for glaucoma filtration surgery (GFS). This eye surgery creates a passage for drainage of aqueous humor (AqH) out of the eye into the sub-Tenon's space with the aim of lowering the intraocular pressure. A major cause of failure of this operation is fibrosis and scarring in the sub-Tenon's space, which will restrict AqH outflow. Intraoperative application of MMC during GFS has increased GFS success rate, presumably mainly by reducing fibrosis after GFS. However, still 10% of glaucoma surgeries fail within the first year. RECENT FINDINGS: In this review, we evaluate risks and benefits of MMC as an adjuvant for GFS. In addition, we discuss possible improvements of its use by adjusting dose and method of administration. SUMMARY: One way of improving GFS outcome is to prolong MMC delivery by using a drug delivery system.
PURPOSE OF REVIEW: Mitomycin C (MMC) is an alkylating agent with extraordinary ability to crosslink DNA, preventing DNA synthesis. By this virtue, MMC is an important antitumor drug. In addition, MMC has become the gold standard medication for glaucoma filtration surgery (GFS). This eye surgery creates a passage for drainage of aqueous humor (AqH) out of the eye into the sub-Tenon's space with the aim of lowering the intraocular pressure. A major cause of failure of this operation is fibrosis and scarring in the sub-Tenon's space, which will restrict AqH outflow. Intraoperative application of MMC during GFS has increased GFS success rate, presumably mainly by reducing fibrosis after GFS. However, still 10% of glaucoma surgeries fail within the first year. RECENT FINDINGS: In this review, we evaluate risks and benefits of MMC as an adjuvant for GFS. In addition, we discuss possible improvements of its use by adjusting dose and method of administration. SUMMARY: One way of improving GFS outcome is to prolong MMC delivery by using a drug delivery system.
Authors: Ralph J S van Mechelen; Jarno E J Wolters; Marjolein Herfs; Christian J F Bertens; Marion Gijbels; Leonard Pinchuk; Theo G M F Gorgels; Henny J M Beckers Journal: Transl Vis Sci Technol Date: 2022-08-01 Impact factor: 3.048
Authors: Inês C F Pereira; Rosanne van de Wijdeven; Hans M Wyss; Henny J M Beckers; Jaap M J den Toonder Journal: Eye (Lond) Date: 2021-06-14 Impact factor: 3.775